Pro­to­cols: Valeant sheds as­sets, but falls short on con­sen­sus; What if vot­ers got a chance to weigh in on your tri­al?

Valeant CEO Michael Pear­son wheeled and dealed his way in­to a bio­phar­ma cat­a­stro­phe. And now his suc­ces­sor, Joseph Pa­pa, is try­ing to wheel and deal his way out. The com­pa­ny’s Q2 re­view in­clud­ed plans to fol­low up on re­cent as­set sales to help pay off debt. But Valeant al­so failed to per­form ac­cord­ing to con­sen­sus es­ti­mates, rais­ing some fresh con­cerns about the com­pa­ny. Valeant’s shares are down 90% off their 12-month peak.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.